Chempartner Pharmatech Co.Ltd(300149) 2021 special statement on deduction of operating income
About Chempartner Pharmatech Co.Ltd(300149)
Special statement on deduction of operating income in 2021
[HW] Z 202149no.
We have been entrusted to audit the financial statements of Chempartner Pharmatech Co.Ltd(300149) , including the consolidated and company’s balance sheet as of December 31, 2021, the consolidated and company’s income statement, statement of changes in shareholders’ equity, cash flow statement and notes to relevant financial statements in 2021, On April 29, 2022, the company issued an unqualified audit report numbered Ernst & Young Huaming (2022) Shen Zi No. 61764838b01 with significant uncertainties related to going concern.
In accordance with the provisions of self regulatory guidelines for companies listed on the growth enterprise market of Shenzhen Stock Exchange No. 1 – business handling, Chempartner Pharmatech Co.Ltd(300149) prepared the attached statement of deduction of operating income in 2021 (hereinafter referred to as the “statement”). It is the responsibility of Chempartner Pharmatech Co.Ltd(300149) management to truthfully prepare and disclose the information form and ensure its authenticity, legitimacy and integrity.
Based on our audit work to express our audit opinion on the Chempartner Pharmatech Co.Ltd(300149) financial statements as a whole, we have not found any significant inconsistency between the relevant information contained in the attached situation table and the accounting information we reviewed when we audited the Chempartner Pharmatech Co.Ltd(300149) 2021 financial statements and the relevant contents disclosed in the 2021 financial statements.
This special instruction is only used by Chempartner Pharmatech Co.Ltd(300149) for the disclosure of 2021 annual report, and is not applicable to other purposes.
About Chempartner Pharmatech Co.Ltd(300149)
Special statement on deduction of operating income in 2021 (Continued)
Ernst & Young Huaming (2022) ZZ No. 61764838b02 Chempartner Pharmatech Co.Ltd(300149) (no text on this page)
Ernst & Young Huaming Certified Public Accountants (special general partnership) Chinese certified public accountant: Li Li
Chinese certified public accountant: Zhang Zhuying
Beijing, China April 29, 2022
Chempartner Pharmatech Co.Ltd(300149)
Deduction of operating income in 2021
Specific deductions of the project in the current year and in the previous year (10000 yuan) (10000 yuan)
Amount of operating revenue 1690677914815919
Total amount of deduction items of operating income 615.52 600.30
The total amount of deduction items of operating income accounts for 0.36% and 0.41% of operating income
1、 Business income unrelated to main business
1. Other business income other than normal operation. For example, the income from renting fixed assets, intangible assets, packaging materials, selling materials, using materials into leasing income, selling materials leasing income, non monetary asset exchange of technical service banks, operating entrusted management business, etc., as well as the income of 615.52 in the market and 600.30 in waste materials although included in the main business income Income from the sale of materials and waste materials other than the normal operation of the company. Income from old materials, etc
2. Non qualified financial business income, such as interest income from lending funds; Newly added in the current fiscal year and the previous fiscal year
Income generated from such financial businesses, such as guarantee, commercial factoring, microfinance, financial leasing, pawn and other businesses, —
Except for the financial leasing business carried out for the sale of main products.
3. Income from new trade business in this fiscal year and the previous fiscal year. —
4. Income from related party transactions unrelated to the existing normal business of the listed company.
– –
5. Income from the beginning of the period to the date of merger of subsidiaries under the same control. —
6. Income generated by businesses that do not form or are difficult to form a stable business model. —
Subtotal of business income unrelated to main business 615.52 600.30
2、 Income without commercial substance-
1. Income from transactions or events that do not significantly change the risk, time distribution or amount of the enterprise’s future cash flow. —
2. Income from businesses with significantly unfair transaction prices. —
3. Income from subsidiaries or businesses of business combination obtained by significantly unfair consideration or non transaction in this fiscal year. —
4. Income involved in non-standard audit opinions in audit opinions. —
5. Income from other transactions or events that are not commercially reasonable. —
Subtotal of income without commercial substance —
3、 Other income unrelated to the main business or without commercial substance —
Amount of operating income after deduction 1684522714755889
Person in charge of the enterprise: person in charge of Accounting: person in charge of accounting organization:
